(Reuters) - Heron Therapeutics Inc said its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its main goal in a late-stage trial.
The company, whose shares were up 41 percent in extended trading, said it expects to resubmit a marketing application for the drug to the U.S. FDA in mid-2015.
The company had filed for marketing application for Sustol twice but the FDA had sought additional data.
The drug, Sustol, in combination with two other drugs, was compared with a standard-of-care three-drug regimen.
The percentage of patients who achieved the main goal of complete response was significantly higher in the Sustol group.
Heron shares had closed at $12.35 on the Nasdaq on Thursday.
Reporting by Shailesh Kuber; Editing by Don Sebastian